INTERIM ANALYSIS OF FABRY TESTING IN WESTERN AUSTRALIA RENAL DIALYSIS PATIENTS: THE FoRWARD STUDY

S AKHTER1, S ALEXANDER1, J GOLDBLATT2, S STARK3, D CRAWFORD1, M THOMAS1

1Dept of Nephrology, Royal Perth Hospital, WA; 2Genetics WA (retired); 3National Referral Laboratory (NRL), Adelaide, SA;

AIM: To determine the prevalence of undiagnosed Fabry Disease (FD) in Western Australian (WA) patients on dialysis.

BACKGROUND: FD is a multisystem X-linked lysosomal storage disease due to GLA gene mutations, causing alpha-galactosidase A deficiency (α-GAL A). It presents with peripheral pain & rash in childhood, then premature death from cerebral, cardiac or renal disease, but diagnostic delay averages 10 years. Prevalence of classic symptomatic disease ≈ 1:50,000; screening high-risk populations produces variably greater rates, prior studies reporting 0-1.7% in dialysis populations.

METHODS: A cross-sectional study of all patients on dialysis in WA who provided informed consent were screened for α-Gal A levels by dried blood spot samples (NRL). Low levels were repeated with GLA gene mutation analysis by next generation sequencing. Ethics approval was granted by Royal Perth Hospital REG 14-136; site-specific approval was granted from appropriate authorities; on ANZ Clinical Trials Registry U1111-1163-7629.

RESULTS: Between February 2015 & May 2017, α-Gal A activity was performed on 375 of 1,100 patients, at 12 of 21 dialysis sites. 37 patients had initial low α-Gal A; repeat testing w& GLA genotyping showed NO confirmed FD cases. False low α-Gal A cases were particularly associated with one private unit (?poor sample handling); other cases had relatively more malnutrition & inflammation (?impaired protein synthesis). During the same time period, 19 confirmed new FD cases were added to total known 45 WA FD cases: 2 cardiac, 1 renal, 1 rheumatological, & 15 through cascade genetic testing.

CONCLUSION: Interim analysis of WA dialysis population has shown a prevalence of 0% undiagnosed FD; false positives may occur through sample handling or malnutrition.

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the conference.
/wp-content/uploads/2017/08/Conference-Design-400x400.png
© 2015 - 2016 Conference Design Pty Ltd